FAST NEWS: Antengene Acquires Full Interest in Anti-Tumor Cancer Drug
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
Discover hidden China stock gems in our weekly newsletter